These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 31712383)

  • 1. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.
    Kates M; Matoso A; Choi W; Baras AS; Daniels MJ; Lombardo K; Brant A; Mikkilineni N; McConkey DJ; Kamat AM; Svatek RS; Porten SP; Meeks JJ; Lerner SP; Dinney CP; Black PC; McKiernan JM; Anderson C; Drake CG; Bivalacqua TJ
    Clin Cancer Res; 2020 Feb; 26(4):882-891. PubMed ID: 31712383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
    Roumiguié M; Compérat E; Chaltiel L; Nouhaud FX; Verhoest G; Masson-Lecomte A; Colin P; Audenet F; Houédé N; Larré S; Xylinas E; Brunelle S; Piana-Thomassin J; Cotte J; Pignot G; Neuzillet Y; Rouprêt M
    World J Urol; 2021 Nov; 39(11):4055-4065. PubMed ID: 32666225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
    Chevalier MF; Schneider AK; Cesson V; Dartiguenave F; Lucca I; Jichlinski P; Nardelli-Haefliger D; Derré L
    Eur Urol; 2018 Nov; 74(5):540-544. PubMed ID: 30033046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.
    Aydin AM; Baydar DE; Hazir B; Babaoglu B; Bilen CY
    World J Urol; 2020 Oct; 38(10):2537-2545. PubMed ID: 31900581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
    Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
    Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette-Guérin Therapy.
    Fukumoto K; Kikuchi E; Mikami S; Hayakawa N; Matsumoto K; Niwa N; Oya M
    Ann Surg Oncol; 2018 Aug; 25(8):2484-2491. PubMed ID: 29717423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
    Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
    Front Immunol; 2020; 11():615091. PubMed ID: 33584702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.
    Eich ML; Chaux A; Guner G; Taheri D; Mendoza Rodriguez MA; Rodriguez Peña MDC; Baras AS; Hahn NM; Drake C; Sharma R; Bivalacqua TJ; Rezaei K; Netto GJ
    Hum Pathol; 2019 Jul; 89():24-32. PubMed ID: 31026471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
    Broughton EI; Gooden KM; Mycock KL; Rajkovic I; Taylor-Stokes G
    BMC Urol; 2022 Feb; 22(1):27. PubMed ID: 35219307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical BCG Induces CD4
    Kates M; Nirschl T; Sopko NA; Matsui H; Kochel CM; Reis LO; Netto GJ; Hoque MO; Hahn NM; McConkey DJ; Baras AS; Drake CG; Bivalacqua TJ
    Cancer Immunol Res; 2017 Jul; 5(7):594-603. PubMed ID: 28588015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer.
    Pichler R; Fritz J; Zavadil C; Schäfer G; Culig Z; Brunner A
    Oncotarget; 2016 Jun; 7(26):39916-39930. PubMed ID: 27221038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders.
    Pierconti F; Raspollini MR; Martini M; Larocca LM; Bassi PF; Bientinesi R; Baroni G; Minervini A; Petracco G; Pini GM; Patriarca C
    Virchows Arch; 2020 Aug; 477(2):269-277. PubMed ID: 32034486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer.
    Abou Chakra M; Luo Y; Duquesne I; A O'Donnell M
    Front Biosci (Landmark Ed); 2024 Aug; 29(8):295. PubMed ID: 39206898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC).
    Delcourt C; Gemival P; Nouhaud FX; Gobet F; Gillibert A; Ferlicot S; Sabourin JC; Irani J; Pfister C
    World J Urol; 2020 Jun; 38(6):1517-1524. PubMed ID: 31486884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of immunotherapy in bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
    Mukherjee N; Svatek RS; Mansour AM
    Urol Oncol; 2018 Mar; 36(3):103-108. PubMed ID: 29429897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
    Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
    Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment.
    Civriz AH; Teke K; Akdas EM; Dillioglugil O; Vural C; Yaprak Bayrak B
    Urol Oncol; 2023 Dec; 41(12):486.e1-486.e13. PubMed ID: 37690934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.